LOS ANGELES, Dec. 7, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced the establishment of an agreement with a major cancer
research group, Alliance Foundation Trials, LLC (AFT), for the
phase 3 registrational trial of its cancer immunotherapy ICT-107 in
patients with newly diagnosed glioblastoma. AFT in conjunction with
the Alliance for Clinical Trials in Oncology comprises nearly
10,000 cancer specialists at hospitals, medical centers, and
community clinics across the United States. AFT will support the
phase 3 trial by providing access to its large network of clinical
sites and patients, with the goal of accelerating patient
enrollment in the trial. Multiple phase 3 clinical trial sites have
been opened for patient enrollment in the US, with additional sites
anticipated to open in Canada and
Europe in the coming weeks and
months.
Andrew Gengos, ImmunoCellular
Chief Executive Officer, commented: "Working in collaboration with
AFT has the potential to significantly accelerate enrollment in the
ICT-107 phase 3 trial, and to engage the participation of important
clinical sites throughout in the US. AFT is one of the most highly
respected cancer organizations in America, and we are appreciative
of their endorsement and support for our registrational trial."
ImmunoCellular has reached agreement with the FDA on a Special
Protocol Assessment (SPA) with respect to the primary and secondary
endpoints as well as the statistical plan for the phase 3 trial.
ImmunoCellular has also been awarded a $19.9
million grant from the governing Board of the California
Institute for Regenerative Medicine (CIRM), California's stem cell agency, to implement
the phase 3 registration trial.
About Alliance Foundation Trials, LLC
Alliance Foundation Trials, LLC (AFT) is a research organization
that develops and conducts cancer clinical trials, working closely
with pharmaceutical partners, research collaborators and the
Alliance for Clinical Trials in Oncology member network. AFT seeks
to fulfill the vision of the Alliance for Clinical Trials in
Oncology to reduce the impact of cancer on people by uniting a
broad community of scientists and clinicians from many disciplines,
committed to discovering, validating and disseminating effective
strategies for the prevention and treatment of cancer. AFT is
funded wholly by private entities and does not use any public
funding resources.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a dendritic cell-based immunotherapy targeting
multiple tumor-associated antigens on glioblastoma stem cells, is
open for patient enrollment. ImmunoCellular's pipeline also
includes: ICT-121, a dendritic cell immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
dendritic cell immunotherapy targeting antigens on ovarian cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer-killing T cells.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the development and
commercialization of ICT-107, initiation of a phase 3 study of
ICT-107 and the potential to accelerate the study through the
relationship with the AFT, the advancement of the ICT-121 phase 1
trial, the development of our preclinical Stem-to-T-cell program
and our ability to achieve our other clinical, operational and
financial goals. These statements are based on ImmunoCellular's
current expectations and involve significant risks and
uncertainties, including those described under the heading "Risk
Factors" in ImmunoCellular's most recently filed quarterly report
on Form 10-Q and annual report on Form 10-K. Except as required by
law, ImmunoCellular undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-alliance-foundation-trials-llc-for-ict-107-phase-3-registrational-trial-in-glioblastoma-300188359.html
SOURCE ImmunoCellular Therapeutics, Ltd.